How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?  

Since data suggests that at least 50% of relapses after CD19 CAR-T are related to loss of CD19 antigen, I would avoid using any CD19 targeting antibody (Loncastuximab tesirine or tafasitamab). I would also avoid using cytotoxic chemotherapy because the vast majority of such patients have chemor...